Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 9/20 | 0.43 |
| ▸ | BMP1 | P13497 | 2/20 | 0.43 |
| ▸ | SERPINE1 | P05121 | 4/20 | 0.39 |
| ▸ | TACR1 | P25103 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5148330 | 0.93 | CETP (0.44) | CETPBMP1SERPINE1TACR1LTB4R2 | |
| SCHEMBL5147175 | 0.85 | TACR1 (0.46) | SERPINE1TACR1 | |
| SCHEMBL5150794 | 0.84 | SERPINE1 (0.47) | CETPBMP1SERPINE1TACR1 | |
| SCHEMBL5149890 | 0.83 | TACR1 (0.39) | CETPSERPINE1TACR1LMNA | |
| SCHEMBL5148340 | 0.83 | TACR1 (0.41) | CETPSERPINE1TACR1 | |
| SCHEMBL5148326 | 0.83 | TACR1 (0.39) | SERPINE1TACR1 | |
| SCHEMBL5148343 | 0.82 | TACR1 (0.40) | CETPSERPINE1TACR1 | |
| SCHEMBL5148349 | 0.81 | CETP (0.41) | CETPSERPINE1TACR1LMNA | |
| SCHEMBL5671215 | 0.80 | CETP (0.50) | CETPBMP1SERPINE1 | |
| SCHEMBL5148332 | 0.80 | SERPINE1 (0.37) | SERPINE1TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | JAPAN TOBACCO INC. (JP) | 2007-03-08 | — | — | US | claimed |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | JAPAN TOBACCO INC. (JP) | 2006-11-30 | — | — | US | claimed |
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | JAPAN TOBACCO INC. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | JAPAN TOBACCO INC. (JP) | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | CETP, PCSK9, LIPA | CETP 1/4885BMP1 3242/4885SERPINE1 90/4885 |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | CETP, SI, LIPC | CETP 1/4885BMP1 3401/4885SERPINE1 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.